Bibliography
- Fredholm BB, IJzerman AP, Jacobson KA, et al. International union of pharmacology. XXXV: Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001;53:527-52
- Akkari R, Burbiel JC, Hockemeyer J, Muller CE. Recent progress in the development of adenosine receptor ligands as anti-inflammatory drugs. Curr Top Med Chem 2006;6:1375-99
- Jacobson KA, Gao Z. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006;5:247-64
- Dhalla AK, Shryock JC, Shreeniwas R, Beraldinelli L. Pharmacology and therapeutic application of A1 adenosine receptor ligands. Curr Top Med Chem 2003;3:369-85
- Gao Z, Jacobson KA. Emerging adenosine receptor agonists. Expert Opin 2007;12:479-92
- Jacobson MA. Adenosine receptor agonists. Expert Opin Ther Patents 2002;12:489-501
- Belardinelli L, Lerman BB. Electrophysiological basis for use of adenosine in the diagnosis and treatment of cardiac arrhythmias. Br Heart J 1990;63:3-34
- Lerman BB, Belardinelli L. Cardiac electrophysiology of adenosine. Basis and clinical concepts. Circulation 1991;83:1499-509
- Belardinelli L, Shryock JC, Song Y, et al. Ionic basis of the electrophysiological actions of adenosine on cardiomyocytes. FASEB J 1995;5:359-65
- DiMarco JP, Sellers TD, Lerman BB, et al. Diagnostic and therapeutic use of adenosine in patients with supraventricular tachycardias. J Am Coll Cardiol 1985;6:417-25
- Wang D, Shryock JC, Belardinelli L. Cellular basis for the negative dromotropic effect of adenosine on rabbit single atrioventricular nodal cell. Cir Res 1996;78:697-706
- Zablocki JA, Wu l, Shryock J, Beraldinelli L. Partial A1 adenosine receptor agonist from a molecular perspective and their potential use as chronic ventricular rate control agents during atrial fibrillation. Curr Top Med Chem 2004;4:839-54
- Hoffman BB, Dall'Aglio E, Hollenbeck C, et al. Suppression of free fatty acids and triglycerides in normal and hypertriglyceridemic rats by adenosine receptor agonist phenylisopropyladenosine. J Pharmacol Exp Ther 1986;239:715-8
- Roden M, Price TB, Perseghin G, et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 1996;97:2859-65
- Gardner CJ, Twissell DJ, Coates J, Strong P. The effects of GR79236 on plasma fatty acid concentrations, heart rate and blood pressure in the conscious rats. Eur J Pharmacol 1994;257:117-21
- Fatholahi M, Xiang Y, Wu Y, et al. A novel partial agonist of the A1-adenosine receptor and evidence of receptor homogeneity in adipocytes. J Pharmacol Exp Ther 2006;317:676-84
- Wu WP, Hao JX, Halldner L, et al. Increased nociceptive response in mice lacking the adenosine A1 receptor. Pain 2005;113:395-404
- Sawynok J. Adenosine receptor activation and nociception. Eur J Pharmacol 1998;347:1-11
- Gordh T, Karlsten R, Kristensen J. Intervention with spinal NMDA, adenosine, and NO systems for pain modulation. Ann Med 1995;27:229-34
- Mizumura T, Auchampach JA, Linden J, et al. PD 81,723 an allosteric enhancer of the A1 adenosine receptor, lowers the threshold for ischemic preconditioning in dogs. Cir Res 1996;79:415-23
- Miura T, Tsuchida A. Adenosine and preconditioning revisited. Clin Exp Pharm Physiol 1999;26:92-9
- Liu GS, Thornton J, Van Winkle DM, et al. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation 1991;84:350-6
- Wang D, Beraldinelli L. Mechanism of the negative inotropic effect of adenosine in guinea pig atrial myocytes. Am J Physiol 1994;267:H2420-9
- Wu L, Belardinelli L, Zablocki JA, et al. A partial agonist of the A1-adenosine receptor selectively slows AV conduction in Guinea pig hearts. Am J Physiol Heart Cir 2001;280:H334-43
- Stephenson RP. A modification of receptor Theory. Br J Pharmacol 1997;120:106-20
- Srinivas M, Shryock JC, Dennis DM, et al. Differential A1 adenosine receptor reserve for two actions of adenosine on guinea pig atrial myocytes. Mol Pharmacol 1997;52:683-91
- Song Y, Wu L, Shryock JC, Beralinelli L. Selective attenuation of isoproterenol-stimulated arrhythmic activity by a partial agonist of adenosine A1 receptor. Circulation 2002;105:118-23
- Sako Y, Grill VE. A 48-hours lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and B cell oxidation through a process likely coupled to fatty acid oxidation. Endocrinology 1990;127:1580-9
- Boden G, She P, Mozzoli M, et al. Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-{Kappa}B pathway in rat liver. Diabetes 2005;54:3458-65
- Itani SI, Ruderman NB, Schmieder F, Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol protein kinase C and IKappaB-alpha. Diabetes 2002;51:2005-11
- Dhalla AK, Wong MY, Voshol PJ, et al. A1- adenosine receptor partial agonist lowers plasma FFA and improves insulin resistance induced by high-fat diet in rodents. Am J Physiol Endocrinol Metab 2007;292:E1358-63
- Ferrannini E, Barrett EJ, Bevilacqua S, DeFronzo RA. Effect of fatty acids on glucose production and utilization in man. J Clin Invest 1983;72:1737-47
- Karlsten R, Kristensen JD, Gordh T. R-Phenylisopropyl-adenosine increases spinal cord blood flow after intrathecal injection in the rat. Anesth Analg 2002;75:972-6
- Ellenbogen KA, O'Neill G, Prystowsky EN, et al. Trial to evaluate the management of paroxysmal supraventricular tachycardia during an electrophysiology study with Tecadenoson. Circulation 2005;111:3202-8
- Prystowsky EN, Niazi I, Curtis AB, et al. Termination of paroxysmal supraventricular tachycardia by tecadenoson (CVT-510), a novel A1-adenosine receptor agonist. J Am Coll Cardiol 2003;42:1098-102
- Peterman C, Sanoski CA. Tecadenoson: a novel, selective A1 adenosine receptor agonist. Cardiol Rev 2005;13:315-21
- Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find. Exp Clin Pharmacol 2003;25:831-55
- Aderis Pharmaceuticals: Safety and efficacy study of an A1-adenosine receptor agonist to slow heart rate atrial fibrillation 2005; Available from: http//:www.clinicalstrials.gov./ct/show/NCT00040001?order=1 [Last accessed October 5 2008]
- Morrison CF, Elzein E, Jiang B, et al. Structure-affinity relationships of 5′-aromatic ethers and 5′-aromatic sulfides as partial A1 adenosine agonists, potential supraventricular anti-arrhythmic agents. Bioorg Med Lett 2004;14:3793-7
- Klotz KN. Adenosine receptors and their ligands. Schmiedebergs Arch Pharmacol 2000;362:382-91
- Yan L, Burbiel JC, Maass A, Muller CE. Adenosine receptor agonists from basic medicinal chemistry to clinical development. Expert Opin Emerg Drugs 2003;8:537-76
- CV Therapeutics Inc. Method of treating arrhythmias comprising administration of an A1 adenosine agonist with a beta blocker, calcium channel blocker, or a cardiac glycoside. WO03088978; 2003
- Hoffman BB, Chang H, Dall'Agilo E, Reaven GM. Desensitization of adenosine receptor-mediated inhibition of lipolysis. The mechanism involves the development of enhanced cyclic adenosine monophosphate accumulation in tolerant adipocytes. J Clin Invest 1986;78:185-90
- Green A. Adenosine receptor down-regulation and insulin resistance following prolonged incubation of adipocytes with an A1 adenosine receptor agonist. Pharmacol Rev 1984;36:165-222
- Green A, Johnson JL, Milligan G. Down-regulation of Gi subtypes by prolonged incubation of adipocytes with an A1 adenosine receptor agonist. J Biol Chem 1990;265:5206-10
- Qu X, Cooney G, Donnelly R. Short-term metabolic and haemodynamic effects of GR79236 in normal and fructose-fed rats. Eur J pharmacol 1997;338:269-76
- Webster JM, Heseltine L, Taylor R. In vitro effect of adenosine agonist GR79236 on insulin sensitivity of glucose utilization in rat soleus and human rectus abdominus muscle. Biochim Biophys Acta 1996;1316:109-13
- IJzerman AP, Van Der Wenden NM, Van Galen PJM, et al. Adenosine and adenine nucleotides: from molecular biology to integrative physiology. Proceedings of the International Symposium on Adenosine and Adenine Nucleotides; 5th, 1994; Publisher: Kluwer, Boston, Mass; 1995. p. 27-37
- Aventis Pharma Deutshland. Novel adenosine analogues and their use as pharmaceutical agents WO04003002; 2004
- Dhalla AK, Melissa S, Smith M, et al. Antilipolytic activity of a novel partial A1 adenosine receptor agonist devoid of cardiovascular effects: Comparison with nicotinic acid. J Pharmacol Exp Ther 2007;321:327-33
- CV Therapeutics Inc. Partial and full agonists of A1 adenosine receptors. US Patent 7157440; 2007
- CV Therapeutics Inc. A1 adenosine receptor agonists. US Patent 7271157; 2007
- Liang HX, Belardinelli L, Ozeck MJ, Shryock JC. Tonic activity of the rat adipocyte A1-adenosine receptor. Br J Pharmacol 2002;135:1457-66
- Dolphin AC, Forda SR, Scott RH. Calcium-dependent currents in cultured rat dorsal root ganglion neurones are inhibited by an adenosine analogue. J Physiol (Lond) 1986;373:47-61
- Pan WJ, Osmanovic SS, Shefner SA. Characterization of the adenosine A1 receptor-activated potassium current in rat locus ceruleus neurons. J Pharm Exp Ther 1995;273:537-44
- Sawynok J. Purines in pain management. Curr Opin CPNS Invest Drugs 1999;1:27-38
- Dickenson AH, Suzuki R, Reeve AJ. Adenosine as a potential analgesic target in inflammatory and neuropathic pain. CNS Drugs 2000;13:77-85
- Sollevi A, Belfrage M, Lundberg T, et al. Systemic adenosine infusion: a new treatment modality to alleviate neuropathic pain. Pain 1995;61:155-8
- Lynch ME, Clark AJ, Sawyonk J. Intravenous adenosine alleviates neuropathic pain: a double blind placebo controlled crossover trial using an enriched enrollment design. Pain 2003;103:111-7
- Wagner H, Krizman-Milavec M, Gadient F, et al. General pharmacology of SDZ WAG-994, a potent selective and orally active adenosine A1 receptor agonist. Drug Dev Res 1995;34:276-88
- Seymour RA, Hawkesford CM, Mill CM, et al. The efficacy of a novel adenosine agonist (WAG 994) in postoperative dental pain. Br J Clin Pharmacol 1999;47:675-80
- Sneyd JR, Langton JA, Allan LG, et al. Multicenter evaluation of the adenosine agonists GR79236X in patients with dental pain after third molar extraction. Br J Anaesth 2007;98(5):672-6
- Meisner PD, et al. A multicenter randomized double-blind, placebo-controlled, parallel group study to evaluate the efficacy and tolerability of a 14 day treatment course of GW493838 50 mg compared to placebo in subjects with peripheral neuropathic pain (GlaxoSmithkline study A1A20004) [abstract 637-P243]. 11th World Congr. Pain; 21-26 August 2005; Sydney
- Bayer. Partial and full agonists of A1 adenosine receptors. WO0773855; 2007
- Chang LCW, Von Kuenzel JK, Mulder-Krieger T, et al. A series of ligands displaying a remarkable agonistic-antagonistic profile at the adenosine A1 receptor. J Med Chem 2005;48(6):2045-203
- Bays M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2007;29(5):359-73
- Zannikos Peter N, Rohatagi Shashank Jensen, Bradford K. Pharmacokinetic-pharmacodynamic modeling of the antilipolytic effects of an adenosine receptor agonist in healthy volunteers. J Clin Pharmacol 2001;41(1):61-9
- Elzein E, Kalla R, Li X, et al. N6-Cycloalkyl-2-substituted adenosine derivatives as selective, high affinity adenosine A1 receptor agonists. Bioorg Med Chem Lett 2007;17:161-6
- DailyDrugNews.com (Daily Essentials) 2000